Conatus Pharmaceuticals Culture Company

Dr. David T. Hagerty, M.D., has been an Executive Vice President of Clinical Development at Conatus Pharmaceuticals Inc. since October 2014. Dr. Hagerty has been an Independent consultant in clinical development since April 2013. He served as Senior Vice President and Chief Marketing Officer of Ardea Biosciences, Inc. from March 1, 2011 to 2013. He served as a Vice President of Immunology and Rheumatology Clinical Research at Biogen Idec Inc. from 2006 to 2011. In this role, he was in charge of the Late Development Rheumatology Group and played a lead role in the joint development of Rituxan??? (rituximab) for rheumatoid arthritis and lupus with development partner, Genentech. Dr. Hagerty held several management roles at the Bristol-Myers Squibb Pharmaceutical Research Institute from 1997 to 2006, where he served as Executive Director of Immunology Global Clinical Research and was the medical lead for the Orencia??? clinical development program. His earlier career included faculty and laboratory research duties at Washington University School of Medicine. Dr. Hagerty served for five years in the Medical Corps of the United States Navy and was recalled to Active Duty in Operation Desert Storm. He is Board Certified in internal medicine and nephrology and has been United Network for Organ Sharing (UNOS) certified as a transplant physician. Dr. Hagerty holds an M.D. from St. Louis University of Medicine and a B.S. degree from the University of Notre Dame.

Dr. Alfred P. Spada, Ph.D., has been Executive Vice President of Research and Development at Conatus Pharmaceuticals Inc. since February 2015. Dr. Spada has been the Chief Scientific Officer of Conatus Pharmaceuticals Inc. since April 2012. Dr. Spada served as Senior Vice President of Research & Development at Conatus Pharmaceuticals Inc. since July 2005. Dr. Spada CoFounded Conatus Pharmaceuticals, Inc. in 2005. he has over twenty years of experience in the pharmaceutical and biotechnology industries. Dr. Spada served as Vice President of Preclinical and Pharmaceutical Development of Idun Pharmaceuticals, Inc. from 2000 to 2005. Prior to joining Idun Pharmaceuticals, Inc., he served as Department Director at Rhone-Poulenc Rorer (Aventis Pharmaceuticals as of December 1999) from 1990 to 2000 with responsibility for medicinal chemistry efforts in the area of cardiovascular disease. His team developed clinical candidates for the treatment of acute myocardial infarction, thrombotic disorders, coronary restenosis and lipid lowering. From 1985 to 1990, Dr. Spada held a series of positions with increasing responsibilities at Rorer Pharmaceuticals, Inc. during which he managed a team of chemists responsible for creating effective pharmaceutical compounds with potential use in the treatment of congestive heart failure and myocardial ischemia. Dr. Spada was awarded a B.S. degree in Chemistry with High Honors from Worcester Polytechnic Institute and a Ph.D. in Chemistry from the Massachusetts Institute of Technology. He also conducted Post-Doctoral research at Yale University.

Charles Cashion serves as the Sr. VP and CFO of Conatus Pharmaceuticals Inc.. Charles started at Conatus Pharmaceuticals Inc. in Jul of 2005. Charles currently resides in the Greater San Diego Area.

David Hagerty serves as the Executive Vice President, Chief Development Officer of Conatus Pharmaceuticals Inc.. David started at Conatus Pharmaceuticals Inc. in Oct of 2014. David currently resides in the Greater San Diego Area.

Shelly Vandertie serves as the Vice President, Finance of Conatus Pharmaceuticals Inc.. Shelly started at Conatus Pharmaceuticals Inc. in Jan of 2007. Shelly currently resides in the Greater San Diego Area.

Alfred Spada serves as the EVP and CSO of Conatus Pharmaceuticals Inc.. Alfred currently resides in the Greater San Diego Area.

Keith Marshall serves as the EVP COO/CFO of Conatus Pharmaceuticals Inc.. Keith currently resides in the Greater San Diego Area.

Alan Engbring serves as the Executive Director, Investor Relations and Corporate Communications of Conatus Pharmaceuticals Inc.. Alan currently resides in the Greater San Diego Area.